Mayo Clinic to Provide Clinical Expertise across Multiple Disease Indications Second Genome to Apply Proprietary Drug Discovery Platform To Identify Microbiome Mediated Mechanisms of Disease South San Francisco, CA. October 7, 2014 – Second Genome, Inc., a leader in the development of novel medicines through innovative microbiome science, has entered into an extensive partnership with the […]
Former Pfizer Executive to Lead R&D at Second Genome South San Francisco, Calif., September 9, 2014 – Second Genome, Inc., a leader in the development of novel medicines through innovative microbiome science, announced today that it has appointed Karim Dabbagh, Ph.D., as the company’s Chief Scientific Officer. In this new position, Dr. Dabbagh will be […]
South San Francisco, Calif., May 2, 2014 – Second Genome announced today that it has entered into an agreement with Pfizer Inc. to conduct extensive microbiome research in a large observational study aimed at gaining new insights into obesity and metabolic disease. The goal of the study is to evaluate numerous clinical factors and the […]
The role of gut bacteria in ulcerative colitis to be the focus of pharmaceutical collaboration in microbiome R&D In a separate announcement, Second Genome completes third tranche of $11.5 Million Series A financing and expands board of directors and scientific advisors San Bruno, CA, June 5, 2013—Second Genome, Inc. announced today that the company has […]
Second Genome brings microbiome science to the discovery and development of therapeutic products. The company has established a pipeline of microbiome modulators that impact infection, immunity and metabolic diseases. Second Genome’s development pipeline is fueled by novel technologies for identifying, screening and scientifically validating product candidates and microbial biomarkers. Second Genome’s technologies have been rigorously validated through partnerships with leading pharmaceutical and nutrition companies, as well as academic and governmental research institutions.